Desoxycorticosterone Acetate

Summary

Desoxycorticosterone Acetate (CHEMBL1200542) is an approved small molecule (ATC H02AA03).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: H02AA03
• Chemistry: 372.5 Da · C23H32O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200542
Name	Desoxycorticosterone Acetate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5952
ATC	H02AA03
Molecular formula	C23H32O4
Molecular weight	372.5
InChIKey	VPGRYOFKCNULNK-ACXQXYJUSA-N

SMILES: CC(=O)OCC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C

IUPAC name: [2-[(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate

Also known as: Deoxycorticosterone, Deoxycorticosterone acetate, Desoxicortona, Desoxycorticosterone, Desoxycorticosterone acetate, Desoxycortone, Desoxycortone acetate, Doca, NSC-11319, NSC-9567, Percorten, SID29215003

Patent coverage: 3,493 distinct patent families (11,491 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Microtubule-associated protein tau, Survival motor neuron protein, Prelamin-A/C, Menin/Histone-lysine N-methyltransferase MLL, Aldehyde dehydrogenase 1A1.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MAPT	6.75	Potency	177.8	nM	CHEMBL_ACT_4012904
SMN1	5.8	Potency	1585	nM	CHEMBL_ACT_3882655
LMNA	5.4	Potency	3981	nM	CHEMBL_ACT_3623033

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).